Derm-Biome Pharmaceuticals announced that its novel compound DB-006 demonstrated superior efficacy in a preclinical model of atopic dermatitis (AD), significantly reducing itch, inflammation, epithelial thickening, and IgE levels. DB-006 outperformed leading topical AD drugs ZORYVE and VTAMA and also showed antimicrobial activity against Staphylococcus aureus, a common trigger of eczema flares. This positions DB-006 as a promising steroid-free topical treatment for mild to moderate AD, addressing a large market need as AD prevalence rises globally. Further studies are underway to confirm its mechanism and potential multi-action benefits.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
